KRAS and adenocarcinoma: It is also conceivable that DARPP-32 might contribute to TKI therapy-refractory growth in adenocarcinomas in which additional downstream genetic alterations exist in genes like RET, ALK, BRAF, or KRAS, although such studies are yet to be conducted.